Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
about
Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures.Pharmacogenetics guided anticoagulation.Metabolic differences of current thienopyridine antiplatelet agents.Perioperative management of anticoagulation in elective surgery.Assessing post-treatment platelet reactivity: a focus on patient selection and setting.Prodrugs design based on inter- and intramolecular chemical processes.Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction.Platelet function inhibitors and platelet function testing in neurointerventional procedures.Clopidogrel Response Variability: Review of the Literature and Practical Considerations.Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.Cangrelor for treatment during percutaneous coronary intervention.A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats.Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.Prasugrel, a Platelet P2Y12 Receptor Antagonist, Improves Abnormal Gait in a Novel Murine Model of Thrombotic Hindlimb IschemiaThe PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease.P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?Clopidogrel versus prasugrel: times are changing, but not for everyone.First report of a subacute stent thrombosis in a prasugrel resistant patient successfully managed with ticagrelor.Perioperative management of anticoagulation in elective surgery.
P2860
Q34805121-62065857-1C51-4395-AE12-03C2C97383E3Q36939417-75CC8174-6000-422A-804E-52D4A192ECECQ37808224-FD804112-9EDA-4E9C-8CE4-0E20EAF547D1Q38071707-0A2D67BD-1608-4DD0-A7BC-A2C52B27D71DQ38100294-F94ACD63-3AE8-4A61-9CBC-6AAF7372622CQ38132923-35E20D61-A27E-4E32-9C1B-8DAD7E857CB9Q38133663-E91ECD3B-DA09-4507-B332-AD215B3775A8Q38189810-9F3983D7-D55F-4548-B28E-94C7A4D98A25Q38233284-84BC93F7-0C19-4D38-B1E1-75141DD548CFQ38640902-8A5296E7-E615-4690-BBB1-B7B1F9236C4CQ38972064-72FFF480-8E5A-4DD6-A1CB-1775CB8A10F4Q39044618-40E6E209-838E-4BC2-AEC7-F1B47B867A10Q39204251-4C9BE8D4-F382-4858-8E04-8BC0180DB13AQ39989728-5C365A85-67E2-4699-9137-FF9C5A731C1EQ41060485-FB995AF0-6BF0-4957-8ED4-7CB8FE9C3D4DQ41110844-0860F7DF-B638-4BEC-A6A1-73B98ADBC402Q41456276-322198F9-8E81-418E-81A2-DB958DC40379Q41511099-B89857B8-085A-4D38-94B5-A2AF1900D873Q43233667-FE18228A-9F90-4445-BDDE-A47132FB25BFQ43781654-73EBCBDF-29F5-4768-B7E5-41862A671609Q45239245-253C81C5-8B62-4D79-AF43-0A6DCEB942CA
P2860
Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
@en
Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
@nl
type
label
Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
@en
Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
@nl
prefLabel
Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
@en
Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
@nl
P2860
P356
P1433
P1476
Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
@en
P2093
Paul P Dobesh
P2860
P304
P356
10.1592/PHCO.29.9.1089
P407
P577
2009-09-01T00:00:00Z